# US 2021/0275698 A1 · Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275698 A1
- Document ID: US20210275698A1
- Status: Published application
- Kind: A1
- Application number: 17/073,153
- Filed: 2020-10-16
- Published: 2021-09-09
- Earliest claimed: 2015-01-21
- Assignees: Cardinal Health 414, LLC
- Applicants: Cardinal Health 414, LLC
- Inventors: Frederick O. COPE
- Web page: https://patentgrep.com/patent/US20210275698A1

## CPC

- A61K 51/065: {conjugates with carriers being macromolecules}
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61K 51/0478: {complexes from non-cyclic ligands, e.g. EDTA, MAG3}
- A61K 51/0491: {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- A61K 51/1018: {against material from animals or humans}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.

## Claims

### Claim 1

A compound comprising a dextran backbone having one or more CD206 targeting moieties and one or more therapeutic agents attached thereto.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein the compound is a compound of Formula (II):
wherein
each X is independently H, L1-A, or L2-R;
each L1 and L2 are independently linkers;
each A independently comprises a therapeutic agent or a detection label or H;
each R independently comprises a CD206 targeting moiety or H;
and
n is an integer greater than zero; and
wherein at least one L2-R comprises a CD206 targeting moiety and at least one L1-A comprises a therapeutic agent.

### Claim 3

A compound comprising a dextran backbone having one or more mannose-binding C-type lectin receptor targeting moieties and one or more therapeutic agents attached thereto.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein the compound is a compound of Formula (II):
wherein
each X is independently H, L1-A, or L2-R;
each L1 and L2 are independently linkers;
each A independently comprises a therapeutic agent or a detection label or H;
each R independently comprises a mannose-binding C-type lectin receptor targeting moiety or H;
and
n is an integer greater than zero; and
wherein at least one L2-R comprises a mannose-binding C-type lectin receptor targeting moiety and at least one L1-A comprises a therapeutic agent.

### Claim 5

A compound according to any of the previous claims, wherein at least one R is selected from the group consisting of mannose, fucose, and n-acetylglucosamine.

### Claim 6

A compound according to any of the previous claims, wherein at least one A is selected from the group consisting of chemotherapeutic agents; antibiotics; immunological adjuvants; steroids; nucleotides; antigens; peptides; proteins; microRNA; siRNA; and antivirals.

### Claim 7

A compound according to any of the previous claims, wherein at least one A is selected from the group consisting of doxorubicin.

### Claim 8

A compound according to any of the previous claims, wherein at least one A is a metal.

### Claim 9

A compound according to any of the previous claims, wherein at least one A is selected from the group consisting of gadolinium, gallium, silver, and a silver antibiotic.

### Claim 10

A compound according to any of the previous claims wherein at least one L1 is a C2-12 hydrocarbon chain optionally interrupted by up to three heteroatoms selected from the group consisting of O, S and N.

### Claim 11

A compound according to any of the previous claims wherein at least one L1 comprises —(CH2)pS(CH2)qNH—, wherein p and q are integers from 0 to 5.

### Claim 12

A compound according to any of the previous claims wherein at least one L2 is a C2-12 hydrocarbon chain optionally interrupted by up to three heteroatoms selected from the group consisting of O, S and N.

### Claim 13

A compound according to any of the previous claims wherein at least one L2 comprises —(CH2)pS(CH2)qNH—, wherein p and q independently are integers from 0 to 5.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of diagnosing and treating a disease comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-13; and
detecting the detection label at a predetermined location in the subject; wherein the disease is selected from AIDS, HIV infection and Leishmaniasis.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating a disease comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-13; wherein the disease is selected from AIDS, HIV infection and Leishmaniasis.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating a disease comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-13, wherein the disease is an autoimmune disease, an inflammatory disease, or cancer.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of targeting tumor-associated macrophages comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-13.

### Claim 18 (depends on 14, 15, 16, 17)

A method according to any one of claims 14-17 wherein the compound contains has at least one therapeutic agent and at least one detection label.

### Claim 19 (depends on 14, 15, 16, 17, 18)

A method according to any one of claims 14-18 wherein a linker is used to attach the one or more CD206 targeting moieties, one or more mannose-binding C-type lectin receptor targeting moietiesone or more therapeutic agents, and/or the one or more detection labels.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

A method according to any one of claims 14-19 wherein at least one L1 comprises a degradable linker.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

A method according to any one of claims 14-20 wherein at least one L1 comprises a hydrolysable linker.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

A method according to any one of claims 14-21 wherein at least one L1 comprises an acid-sensitive linker.

### Claim 23 (depends on 16, 18, 19, 20, 21, 22)

A method according to any one of claims 16 and 18-22, wherein the disease is rheumatoid arthritis.

### Claim 24 (depends on 16, 18, 19, 20, 21, 22)

A method according to any one of claims 16 and 18-22, wherein the disorder is cancer.

### Claim 25 (depends on 24)

A method according to claim 24, wherein the cancer is a sarcoma, lymphoma, leukemia, carcinoma, blastoma, melanoma, or germ cell tumor.

### Claim 26 (depends on 25)

A method according to claim 25, wherein the cancer is Kaposi's sarcoma.

### Claim 27 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method according to any one of claims 14-26, wherein at least one A is a detection label and the detection label is a fluorophore.

### Claim 28 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method according to any one of claims 14-27, wherein at least one L1-A comprises a chelator.

### Claim 29

A compound of Formula (II):
wherein
each X is independently H, L1-A, or L2-R;
each L1 and L2 are independently linkers;
each A independently comprises a therapeutic agent or a detection label or H;
each R independently comprises a CD206 targeting moiety or H;
and
n is an integer greater than zero; and
wherein at least one X is L1-A wherein L1 comprises a hydrazone and at least one X is L2-R.

### Claim 30

A compound according to any of the previous claims, wherein at least one R is selected from mannose, fucose, and n-acetylglucosamine.

### Claim 31

A compound according to any of the previous claims, wherein at least one A is selected from a chemotherapeutic agent; an antibiotic; an immunological adjuvant; a compounds useful for treating tuberculosis; a steroid; a nucleotide; a peptide; a protein; microRNA; siRNA; an antiviral; an antigens; or a metal.

### Claim 32

A compound according to any of the previous claims, wherein at least one A is a compound useful for treating tuberculosis.

### Claim 33

A compound according to any of the previous claims, wherein at least one A is doxorubicin, isoniazid, gadolinium, gallium, silver, or a silver antibiotic.

### Claim 34

A compound according to any of the previous claims wherein at least one L1 is a C2-12 hydrocarbon chain optionally interrupted by up to three heteroatoms selected from the group consisting of O, S and N.

### Claim 35

A compound according to any of the previous claims wherein at least one L1 comprises —(CH2)pS(CH2)qNH—, wherein p and q are integers from 0 to 5.

### Claim 36

A compound according to any of the previous claims wherein at least one L2 is a C2-12 hydrocarbon chain optionally interrupted by up to three heteroatoms selected from the group consisting of O, S and N.

### Claim 37

A compound according to any of the previous claims wherein at least one L2 comprises —(CH2)pS(CH2)qNH—, wherein p and q independently are integers from 0 to 5.

### Claim 38

A compound according to any of the previous claims, wherein at least one Li-A comprises a chelator.

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of synthesizing a compound according to any of claims 29-38 comprising
a. reacting a dextran-containing moiety having at least one CD206 moiety attached thereto with a lactone to form an oxo-terminated compound;
b. reacting the oxo-terminated compound with N2H4 to form a hydrazine-terminated compound; and
c. reacting the hydrazine-terminated compound with a oxo-containing therapeutic agent.

### Claim 40 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of synthesizing a compound according to any of claims 29-38 comprising
a. reacting a dextran-containing moiety having at least one CD206 moiety attached thereto with N-hydroxy succinimide activated linker to form an carbazate-terminated compound;
b. reacting the carbazate-terminated compound with trifluoroacetic acid to form a hydrazine-terminated compound; and
c. and reacting the hydrazine-terminated compound with a oxo-containing therapeutic agent.

### Claim 41 (depends on 40)

The method of claim 40, wherein the N-hydroxy succinimide activated linker is

### Claim 42 (depends on 39, 40, 41)

The method of any one of claims 39-41, wherein the oxo-containing therapeutic agent is doxorubicin.

### Claim 43 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of synthesizing a compound according to any of claims 29-38 comprising
a. reacting a dextran-containing moiety having at least one CD206 moiety attached thereto with a lactone to form an oxo-terminated compound; and
b. reacting the oxo-terminated compound with an amine-containing therapeutic agent.

### Claim 44 (depends on 43)

The method of claim 43, wherein the amine-containing therapeutic agent is isoniazide.

### Claim 45 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of treating tuberculosis comprising administering to a subject in need thereof a compound according to any one of claims 29-38 wherein at least one A is a compound useful for treating tuberculosis.

### Claim 46 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of diagnosing and treating a macrophage-mediated disorder comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 29-38; and detecting the detection label at a predetermined location in the subject.

### Claim 47 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of treating a macrophage-mediated disorder comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 29-38.

### Claim 48 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method of treating a disease comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 29-37, wherein the disease is an autoimmune disease, an inflammatory disease, or cancer.

### Claim 49 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of targeting tumor-associated macrophages comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 29-38.

### Claim 50 (depends on 45, 46, 47, 48, 49)

A method according to any one of claims 45-49 wherein the compound contains at least one therapeutic agent and at least one detection label.

### Claim 51 (depends on 45, 46, 47, 48, 49, 50)

A method according to any one of claims 45-50 wherein a linker is used to attach the one or more CD206 targeting moieties, one or more therapeutic agents, and/or the one or more detection labels.

### Claim 52 (depends on 45, 46, 47, 48, 49, 50, 51)

A method according to any one of claims 45-51 wherein at least one L1 comprises a degradable linker.

### Claim 53 (depends on 45, 46, 47, 48, 49, 50, 51, 52)

A method according to any one of claims 45-52 wherein at least one L1 comprises a hydrolysable linker.

### Claim 54 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53)

A method according to any one of claims 45-53 wherein at least one L1 comprises an acid sensitive linker.

### Claim 55 (depends on 46, 47, 50, 51, 52, 53, 54)

A method according to any one of claims 46, 47 and 50-54, wherein the macrophage mediated disorder is selected from the group consisting of tuberculosis, AIDS, HIV infection and Leishmaniasis.

### Claim 56 (depends on 48, 50, 51, 52, 53, 54)

A method according to any one of claims 48 and 50-54, wherein the disease is rheumatoid arthritis.

### Claim 57 (depends on 48, 50, 51, 52, 53, 54)

A method according to any one of claims 48 and 50-54, wherein the disorder is cancer.

### Claim 58 (depends on 57)

A method according to claim 57, wherein the cancer is a sarcoma, lymphoma, leukemia, carcinoma, blastoma, melanoma, or germ cell tumor.

### Claim 59 (depends on 57)

A method according to claim 57, wherein the cancer is Kaposi's sarcoma.

### Claim 60 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

A method according to any one of claims 45-59, wherein at least one A is a detection label and the detection label is a fluorophore.

### Claim 61 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

A method according to any one of claims 45-60, wherein at least one L1-A comprises a chelator.

### Claim 62

A compound selected from the group consisting of:
wherein R is mannose; R′ is H or CH3; and n is an integer greater than zero.
